The co-primary endpoints were safety and efficacy: efficacy defined as ≥25% reduction in rectal rV70 in >75% of balloon ...

Dr. Jani highlighted the EMPIRE-1 trial, which evaluated the role of 18F-fluciclovine PET in guiding post-prostatectomy radiotherapy. The study demonstrated an improvement in 3-year freedom from ...

The 67 th American Society for Radiation Oncology (ASTRO) annual meeting held in San Francisco., between September 28 and September 30 was host to the Session16 - GU 4: Quality of Life Outcomes after ...

No patients died of prostate cancer. The 5-year overall survival was 90%.

The 2025 ASTRO annual meeting featured a prostate cancer session and a presentation by Dr. Angela Jia discussing the clinical ...

Dr. Yu began by highlighting that moderately hypofractionated IMRT (MH-IMRT) has been the standard of care for prostate cancer since RTOG 0415 and other landmark studies. 1 At the time this trial was ...

The 2025 ASTRO annual meeting featured a prostate cancer radiation toxicity session and a presentation by Dr. Young Suk Kwon discussing an EPIC-26 longitudinal analyses of prostatic urethral lift ...

The MARCAP Consortium is the largest independent data repository and statistical analysis team, with Dr. Spratt and Dr. Amar Kishan as co-primary investigators. The purpose of the first MARCAP ...

This was a single-center, retrospective analysis of 42 patients with MIBC who underwent TMT at the Moffitt Cancer Center between October 2019 and April 2024 and had ≥1 post-TMT ctDNA (Signatera TM) ...

Stereotactic body radiation therapy (SBRT), defined as the delivery of >5Gy per fraction, has emerged as a well-established standard of care option for the definitive management of localized prostate ...

The PCS5 trial is a Canadian multicenter, open-label, phase III randomized trial that included men with histologically proven, clinically localized prostate cancer with ≥1 high-risk feature (s) ...

At a median follow-up of 19.6 months, the median PSA was 0.028 ng/mL. 18/100 patients developed biochemical recurrence, with a median time to recurrence of 10 months. The biochemical recurrence-free ...